Apnimed, Inc. Common Stock (NASDAQ:APMD) — Market Cap & Net Worth
Market Cap & Net Worth: Apnimed, Inc. Common Stock (APMD)
Apnimed, Inc. Common Stock (NASDAQ:APMD) has a market capitalization of $770.86 Million ($770.86 Million) as of October 10, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #10107 globally and #2711 in its home market, demonstrating a -17.83% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Apnimed, Inc. Common Stock's stock price $18.52 by its total outstanding shares 41623183 (41.62 Million).
Apnimed, Inc. Common Stock Market Cap History: 2026 to 2026
Apnimed, Inc. Common Stock's market capitalization history from 2026 to 2026. Data shows growth from $770.86 Million to $770.86 Million (0.00% CAGR). Check Apnimed, Inc. Common Stock (APMD) share price today for real-time trading data and today's change.
Apnimed, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Apnimed, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see cash efficiency ratio of Apnimed, Inc. Common Stock for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of APMD by Market Capitalization
Companies near Apnimed, Inc. Common Stock in the global market cap rankings as of October 10, 2026. See Apnimed, Inc. Common Stock (APMD) net asset quality to understand what proportion of total assets are financed by equity.
Key companies related to Apnimed, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $129.29 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #366 globally with a market cap of $75.50 Billion USD.
- CSL Ltd (AU:CSL): Ranked #448 globally with a market cap of $63.11 Billion USD ( AU$89.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $129.29 Billion | $510.08 |
| #366 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $75.50 Billion | $746.54 |
| #448 | CSL Ltd | AU:CSL | $63.11 Billion | AU$183.84 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $225.00 |
Apnimed, Inc. Common Stock Historical Marketcap From 2026 to 2026
Between 2026 and today, Apnimed, Inc. Common Stock's market cap moved from $770.86 Million to $ 770.86 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $770.86 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 10th, 2026 the market cap of Apnimed, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $770.86 Million USD |
| MoneyControl | $770.86 Million USD |
| MarketWatch | $770.86 Million USD |
| marketcap.company | $770.86 Million USD |
| Reuters | $770.86 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Apnimed, Inc. Common Stock
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. It offers AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is headquartered in Cambr… Read more